(Q39022901)

1 July 2019

title

Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines (English)

1 reference

1 July 2019

main subject

rubitecan

1 reference

ChEBI release 2020-05-28

1 reference

Gerhard Hamilton

1

1 reference

1 July 2019

Lukas Klameth

series ordinal

2

1 reference

1 July 2019

Barbara Rath

series ordinal

3

1 reference

1 July 2019

Theresia Thalhammer

series ordinal

4

1 reference

1 July 2019

language of work or name

English

0 references

publication date

17 February 2014

1 reference

1 July 2019

published in

Molecules

1 reference

1 July 2019

volume

19

1 reference

1 July 2019

issue

2

1 reference

1 July 2019

page(s)

2077-2088

1 reference

1 July 2019

Creative Commons Attribution 4.0 International

copyright license

start time

17 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The International Epidemiology of Lung Cancer: geographical distribution and secular trends.

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Management of small cell lung cancer: recent developments for optimal care

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Novel strategies for the treatment of small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Second-line therapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Cancer therapies utilizing the camptothecins: a review of the in vivo literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

The p53 network: p53 and its downstream genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES19022077

Cyclin-dependent kinase modulators and cancer therapy

21 January 2018

1 reference

12 December 2020

Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors

1 reference

12 December 2020

Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer

1 reference

12 December 2020

Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB

1 reference

12 December 2020

Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.

1 reference

12 December 2020

Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.

1 reference

12 December 2020

10.3390/MOLECULES19022077

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6271949

1 reference

1 July 2019

PubMed publication ID

24549232

1 reference

1 July 2019